GLP-1 and A1C: Complete Blood Sugar Guide
GLP-1 medications were originally developed to lower blood sugar, and they remain among the most effective medications for improving A1C levels. Whether you are taking semaglutide or tirzepatide for weight loss, diabetes management, or both, understanding how these medications affect your A1C helps you track treatment success and make informed decisions.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for interpretation of lab results and medication decisions.
What A1C Measures
A1C (hemoglobin A1C or HbA1c) measures your average blood sugar over the previous 2-3 months. It reflects the percentage of hemoglobin in your red blood cells that has glucose attached. Because red blood cells live approximately 120 days, A1C provides a time-averaged picture rather than a snapshot.
- Normal: Below 5.7%
- Prediabetes: 5.7% to 6.4%
- Diabetes: 6.5% and above
How GLP-1 Lowers A1C
GLP-1 medications reduce blood sugar through multiple mechanisms:
- Glucose-dependent insulin secretion: GLP-1 stimulates insulin release only when blood sugar is elevated, reducing the risk of hypoglycemia
- Glucagon suppression: Reduces the liver's glucose output when it is not needed
- Slowed gastric emptying: Reduces post-meal blood sugar spikes by slowing carbohydrate absorption
- Weight loss: Fat loss improves insulin sensitivity, which independently lowers blood sugar
- Beta cell protection: GLP-1 may help preserve insulin-producing cells in the pancreas
Expected A1C Improvements
The magnitude of A1C reduction depends on your starting level and medication:
| Starting A1C | Semaglutide Reduction | Tirzepatide Reduction |
|---|---|---|
| 5.7-6.4% (prediabetes) | 0.3-0.5% | 0.4-0.7% |
| 6.5-7.5% (mild diabetes) | 0.8-1.2% | 1.0-1.8% |
| 8.0%+ (uncontrolled) | 1.5-2.0% | 1.8-2.3% |
Tirzepatide has shown somewhat greater A1C reductions than semaglutide in head-to-head trials, likely due to its dual GIP/GLP-1 mechanism. Both medications produce clinically meaningful improvements.
Testing Schedule on GLP-1
Recommended A1C testing frequency during GLP-1 treatment:
- Baseline: Before starting medication
- 3 months: First check after starting; reflects early response
- 6 months: Reflects full dose titration response
- Every 3-6 months: Ongoing monitoring during treatment
If you are taking GLP-1 for weight loss without diabetes, your provider may check A1C less frequently but should still monitor it as part of routine metabolic assessment.
What Your Numbers Mean During Treatment
- A1C dropping from prediabetic to normal: GLP-1 may be preventing diabetes progression, a significant long-term health benefit
- A1C normalizing from diabetic range: Some patients achieve diabetes remission on GLP-1, though this should be monitored as it may return if medication is stopped
- A1C not improving: May indicate need for dose adjustment, medication switch, or additional diabetes treatment
A1C and Weight Loss: The Connection
A1C improvements on GLP-1 come from two sources: the medication's direct blood sugar effects and the metabolic improvement from weight loss. As a general rule, every 1% of body weight lost improves A1C by approximately 0.1%. This means a patient who loses 15% of body weight through GLP-1 treatment might see an additional 1.5% A1C reduction from weight loss alone, on top of the medication's direct effects.
If You Are Not Diabetic
Even if your A1C is normal, GLP-1 medications still affect blood sugar regulation. Non-diabetic patients on GLP-1 typically see their fasting blood sugar drop by 5-15 mg/dL and may notice more stable energy levels throughout the day due to reduced blood sugar variability. This is not a concern, as GLP-1's glucose-dependent mechanism prevents blood sugar from dropping too low.
Getting Started
Whether you are managing diabetes or pursuing weight loss, GLP-1 medications offer significant A1C benefits. Visit Trimi's treatment options page. Compounded semaglutide is $99/month and tirzepatide is $125/month, with provider monitoring included.
Frequently Asked Questions
Will GLP-1 cure my diabetes?
GLP-1 medications can produce diabetes remission in some patients, meaning A1C returns to the normal range. However, this is not considered a cure, as blood sugar may rise again if medication is stopped. Your provider will help develop a long-term management plan.
Can GLP-1 cause low blood sugar?
GLP-1 medications have a low risk of hypoglycemia because they stimulate insulin in a glucose-dependent manner, meaning they primarily work when blood sugar is elevated. The risk increases if you are also taking insulin or sulfonylureas.
How quickly does A1C improve on GLP-1?
Most patients see measurable A1C improvement within 3 months. Maximum improvement typically occurs by 6-9 months as dose titration is completed and weight loss accumulates.
Should I stop my diabetes medications when starting GLP-1?
Never stop diabetes medications without provider guidance. Your Trimi provider or endocrinologist will coordinate medication adjustments as your A1C improves on GLP-1 treatment.
More on Lab Values & GLP-1
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).